Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates

David Bangsberg, Travis C. Porco, C. Kagay, Edwin D. Charlebois, Steven G. Deeks, David Guzman, Richard Clark, Andrew Moss

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The standard view postulates a bell-shaped relationship between adherence to therapy and development of drug-resistant human immunodeficiency virus (HIV), with a resistance peak at a moderate level of adherence. This relationship has not been confirmed empirically. We statistically modeled the relationship between adherence and development of drug resistance, using empirically defined relationships of the rate of viral suppression and drug-resistance-mutation accumulation derived from patients receiving protease-inhibitor-based therapy. We found that the maximal rate of drug resistance occurs at 87% adherence and declines modestly at 100% adherence. Higher levels of viral suppression at 100% adherence (a marker of greater regimen potency) progressively reduce the overall population rate of drug resistance and shift the peak resistance rate to lower levels of adherence.

Original languageEnglish (US)
Pages (from-to)162-165
Number of pages4
JournalJournal of Infectious Diseases
Volume190
Issue number1
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Protease Inhibitors
Drug Resistance
HIV
Viral Drug Resistance
Drug Therapy
Population
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. / Bangsberg, David; Porco, Travis C.; Kagay, C.; Charlebois, Edwin D.; Deeks, Steven G.; Guzman, David; Clark, Richard; Moss, Andrew.

In: Journal of Infectious Diseases, Vol. 190, No. 1, 01.07.2004, p. 162-165.

Research output: Contribution to journalArticle

Bangsberg, D, Porco, TC, Kagay, C, Charlebois, ED, Deeks, SG, Guzman, D, Clark, R & Moss, A 2004, 'Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates', Journal of Infectious Diseases, vol. 190, no. 1, pp. 162-165. https://doi.org/10.1086/420790
Bangsberg, David ; Porco, Travis C. ; Kagay, C. ; Charlebois, Edwin D. ; Deeks, Steven G. ; Guzman, David ; Clark, Richard ; Moss, Andrew. / Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. In: Journal of Infectious Diseases. 2004 ; Vol. 190, No. 1. pp. 162-165.
@article{72a817fbce5242e2801705e0724662c8,
title = "Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates",
abstract = "The standard view postulates a bell-shaped relationship between adherence to therapy and development of drug-resistant human immunodeficiency virus (HIV), with a resistance peak at a moderate level of adherence. This relationship has not been confirmed empirically. We statistically modeled the relationship between adherence and development of drug resistance, using empirically defined relationships of the rate of viral suppression and drug-resistance-mutation accumulation derived from patients receiving protease-inhibitor-based therapy. We found that the maximal rate of drug resistance occurs at 87{\%} adherence and declines modestly at 100{\%} adherence. Higher levels of viral suppression at 100{\%} adherence (a marker of greater regimen potency) progressively reduce the overall population rate of drug resistance and shift the peak resistance rate to lower levels of adherence.",
author = "David Bangsberg and Porco, {Travis C.} and C. Kagay and Charlebois, {Edwin D.} and Deeks, {Steven G.} and David Guzman and Richard Clark and Andrew Moss",
year = "2004",
month = "7",
day = "1",
doi = "10.1086/420790",
language = "English (US)",
volume = "190",
pages = "162--165",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates

AU - Bangsberg, David

AU - Porco, Travis C.

AU - Kagay, C.

AU - Charlebois, Edwin D.

AU - Deeks, Steven G.

AU - Guzman, David

AU - Clark, Richard

AU - Moss, Andrew

PY - 2004/7/1

Y1 - 2004/7/1

N2 - The standard view postulates a bell-shaped relationship between adherence to therapy and development of drug-resistant human immunodeficiency virus (HIV), with a resistance peak at a moderate level of adherence. This relationship has not been confirmed empirically. We statistically modeled the relationship between adherence and development of drug resistance, using empirically defined relationships of the rate of viral suppression and drug-resistance-mutation accumulation derived from patients receiving protease-inhibitor-based therapy. We found that the maximal rate of drug resistance occurs at 87% adherence and declines modestly at 100% adherence. Higher levels of viral suppression at 100% adherence (a marker of greater regimen potency) progressively reduce the overall population rate of drug resistance and shift the peak resistance rate to lower levels of adherence.

AB - The standard view postulates a bell-shaped relationship between adherence to therapy and development of drug-resistant human immunodeficiency virus (HIV), with a resistance peak at a moderate level of adherence. This relationship has not been confirmed empirically. We statistically modeled the relationship between adherence and development of drug resistance, using empirically defined relationships of the rate of viral suppression and drug-resistance-mutation accumulation derived from patients receiving protease-inhibitor-based therapy. We found that the maximal rate of drug resistance occurs at 87% adherence and declines modestly at 100% adherence. Higher levels of viral suppression at 100% adherence (a marker of greater regimen potency) progressively reduce the overall population rate of drug resistance and shift the peak resistance rate to lower levels of adherence.

UR - http://www.scopus.com/inward/record.url?scp=3042842610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042842610&partnerID=8YFLogxK

U2 - 10.1086/420790

DO - 10.1086/420790

M3 - Article

C2 - 15195256

AN - SCOPUS:3042842610

VL - 190

SP - 162

EP - 165

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -